Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone

Maurice Balke, Laura Campanacci, Carsten Gebert, Piero Picci, Max Gibbons, Richard Taylor, Pancras Hogendoorn, Judith Kroep, John Wass, Nicholas Athanasou

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Giant cell tumour of bone (GCTB) is an expansile osteolytic tumour which contains numerous osteoclast-like giant cells. GCTB frequently recurs and can produce metastatic lesions in the lungs. Bisphosphonates are anti-resorptive drugs which act mainly on osteoclasts.Method: In this study, we have examined clinical and radiological outcomes of treatment with aminobisphosphonates on 25 cases of aggressive primary, recurrent and metastatic GCTB derived from four European centres. We also analysed in vitro the inhibitory effect of zoledronic acid on osteoclasts isolated from GCTBs.Results: Treatment protocols differed with several different aminobisphosphonates being employed, but stabilisation of disease was achieved in most of these cases which were refractory to conventional treatment. Most inoperable sacral/pelvic tumours did not increase in size and no further recurrence was seen in GCTBs that had repeatedly recurred in bone and soft tissues. Lung metastases did not increase in size or number following treatment. Zoledronic acid markedly inhibited lacunar resorption by GCTB-derived osteoclasts in vitro.Conclusion: Our findings suggest that bisphosphonates may be useful in controlling disease progression in GCTB and that these agents directly inhibit GCTB - derived osteoclast resorption. These studies highlight the need for the establishment of standardised protocols to assess the efficacy of bisphosphonate treatment of GCTB.

Original languageEnglish
Article number462
JournalBMC Cancer
Volume10
DOIs
Publication statusPublished - Aug 29 2010

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Genetics

Fingerprint Dive into the research topics of 'Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone'. Together they form a unique fingerprint.

Cite this